Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Sarepta Therapeutics Inc. has demonstrated stable adoption of its treatments, reflected in the preliminary 4Q25 net revenue of $259.2 million, which marks a 9% increase from the previous quarter, indicating a strong market presence and potential for growth beyond the $500 million annual sales threshold. The company's ongoing research into additional therapeutic candidates, particularly in its FSHD and DM1 programs, could provide significant upside if initial data supports competitive profiles, suggesting a robust pipeline that may enhance future revenue streams. Furthermore, with the positive outlook for Elevidys, evidenced by its substantial revenue of $110.4 million in 4Q25 translating to an annualized run-rate of approximately $442 million, the expectation is that uptake will continue to rise, contributing positively to Sarepta's financial performance.

Sarepta Therapeutics Inc. recently reported preliminary 4Q25 net revenue for Elevidys at $110.4 million, falling short of consensus expectations, which raises concerns about the company's revenue reliability given the dependence on a limited number of patients for quarterly performance. Management's reiterated expectations for a sales floor of $500 million and plans to expand the sales force may not fully address underlying concerns about the perceived efficacy and safety profiles of Elevidys, particularly as competition in the neuromuscular therapy segment evolves. Additionally, uncertainties regarding the sustainability of revenue growth and potential market share erosion as newer treatments are developed contribute to a negative outlook on the company's long-term financial prospects.